NASDAQ · DXCM
Healthcare · Medical - Devices
$86.45
Up+$1.77 (+2.09%)
Updated Sep 16, 2026, 12:02 PM
SID Score
6.9/10
Composite research score
Smart Money
59/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
DXCM closed at $86.45 after 20 trading sessions, down 3.52% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $84.04 | $87.36 | $83.255 | $86.45 | 5.96M |
| Sep 14, 2026 | $83.92 | $84.98 | $83.76 | $84.68 | 2.54M |
| Sep 11, 2026 | $84.65 | $85.815 | $82.83 | $83.03 | 2.55M |
| Sep 10, 2026 | $83.27 | $84.815 | $82.29 | $84.51 | 3.54M |
| Sep 9, 2026 | $83.93 | $85.16 | $82.795 | $83.88 | 4.18M |
| Sep 8, 2026 | $86.59 | $86.75 | $84.24 | $84.53 | 8.22M |
| Sep 4, 2026 | $88.78 | $89.00 | $87.65 | $87.90 | 2.36M |
| Sep 3, 2026 | $89.73 | $91.00 | $89.05 | $89.71 | 1.68M |
| Sep 2, 2026 | $90.03 | $91.90 | $89.5425 | $89.69 | 1.92M |
| Sep 1, 2026 | $90.83 | $92.335 | $89.91 | $90.14 | 2.15M |
| Aug 31, 2026 | $90.00 | $91.18 | $89.09 | $91.06 | 3M |
| Aug 28, 2026 | $89.805 | $90.84 | $88.825 | $90.82 | 2.55M |
| Aug 27, 2026 | $88.37 | $90.43 | $87.60 | $89.29 | 3.03M |
| Aug 26, 2026 | $88.17 | $89.76 | $87.51 | $88.96 | 3.82M |
| Aug 25, 2026 | $90.731 | $91.14 | $88.78 | $89.16 | 4.11M |
| Aug 24, 2026 | $92.30 | $92.59 | $91.03 | $91.06 | 4.45M |
| Aug 21, 2026 | $89.605 | $92.56 | $89.1964 | $92.34 | 3.48M |
| Aug 20, 2026 | $89.42 | $91.385 | $89.275 | $90.22 | 5.16M |
| Aug 19, 2026 | $90.30 | $91.915 | $89.235 | $89.88 | 8.67M |
| Aug 18, 2026 | $89.49 | $91.4999 | $88.98 | $89.60 | 3.36M |
The latest Smart Investors Daily articles mentioning DXCM.
DXCM research
Company profile and research snapshot.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | Argus Research | Buy | — |
| Aug 3, 2026 | Canaccord Genuity | Buy | — |
| Jul 31, 2026 | BTIG | Buy | — |
| Jul 31, 2026 | Citigroup | Buy | — |
| Jul 31, 2026 | Piper Sandler | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
SAN DIEGO, September 10, 2026--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.
SeekingAlpha · Sep 9, 2026
DexCom, Inc. (DXCM) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 8:00 AM EDTCompany ParticipantsJereme Sylvain - Executive VP, CFO &...
Yahoo · Sep 8, 2026
DexCom has underperformed the broader market over the past year, while analysts remain strongly optimistic about its future prospects.
Yahoo · Sep 4, 2026
DexCom stock has delivered a mixed ride for long term holders, with the share price down about 35.1% over five years even as a Discounted Cash Flow (DCF) estimate points to an intrinsic value that sits meaningfully above the current market price. At the same time, broader valuation checks lean cautious and market based multiples look roughly in line with peers rather than clearly cheap. Over the past five years, DexCom shareholders have seen the stock decline about 35.1%, which puts more...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning DXCM.
